Kayentis
Meylan
About Kayentis
Kayentis, a global leader in eCOA and Decentralized Clinical Trial solutions, empowers pharma, biotech, and CROs to streamline data collection in clinical trials, enhancing simplicity, efficiency, and data quality. Since 2005, Kayentis has spearheaded clinical development, specializing in eCOA solutions across phases I-IV in over 200 indications across more than 20 therapeutic areas. Adapting to the changing landscape, Kayentis is now offering a comprehensive suite of services to support science-driven and patient-centric clinical research, with operational capabilities across the USA, Europe, and Asia.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $28.1M
- Last round: Series Unknown (Mar 2023)
- Website: kayentis.com
- Phone: +33 4 76 00 54 20
Industries & Categories
Medical, Pharmaceutical, Software
Social Profiles
Canonical: https://fsome.com/organization/kayentis-22815 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.